203 related articles for article (PubMed ID: 31815555)
1. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
2. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
Nigro SC; Luon D; Baker WL
Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
[TBL] [Abstract][Full Text] [Related]
3. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
4. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability review of lorcaserin in clinical trials.
Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):53-64. PubMed ID: 31770497
[No Abstract] [Full Text] [Related]
9. Lorcaserin: a review of its use in chronic weight management.
Hoy SM
Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825
[TBL] [Abstract][Full Text] [Related]
10. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
Higgins GA; Fletcher PJ; Shanahan WR
Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.
Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC
Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
[TBL] [Abstract][Full Text] [Related]
13. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
Hurren KM; Dunham MW
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
[TBL] [Abstract][Full Text] [Related]
15. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
16. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
17. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW
Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963
[TBL] [Abstract][Full Text] [Related]
18. Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials.
Weissman NJ; Smith SR; Fain R; Hall N; Shanahan WR
Obesity (Silver Spring); 2017 Jan; 25(1):39-44. PubMed ID: 27888609
[TBL] [Abstract][Full Text] [Related]
19. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
Nguyen CT; Zhou S; Shanahan W; Fain R
Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
[TBL] [Abstract][Full Text] [Related]
20. Novel oral anti-obesity agents: new perspectives with lorcaserin?
Gallwitz B
Drugs; 2013 Apr; 73(5):393-5. PubMed ID: 23532530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
